The Targeting of Nuclear Factor Kappa B by Drugs Adopted for the Prevention and Treatment of Preeclampsia
Preeclampsia (PE) is characterised by high levels and activity of the transcription factor Nuclear Factor kappa B (NFĸB) in the maternal blood and placental cells. This factor is responsible for the regulation of over 400 genes known to influence processes related to inflammation, apoptosis and angi...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/5/2881 |
| _version_ | 1797474879491014656 |
|---|---|
| author | Agata Sakowicz |
| author_facet | Agata Sakowicz |
| author_sort | Agata Sakowicz |
| collection | DOAJ |
| description | Preeclampsia (PE) is characterised by high levels and activity of the transcription factor Nuclear Factor kappa B (NFĸB) in the maternal blood and placental cells. This factor is responsible for the regulation of over 400 genes known to influence processes related to inflammation, apoptosis and angiogenesis, and cellular responses to oxidative stress and hypoxia. Although high NFĸB activity induces hypoxia and inflammation, which are beneficial for the process of implantation, NFĸB level should be reduced in the later stages of physiological pregnancy to favour maternal immunosuppression and maintain gestation. It is believed that the downregulation of NFĸB activity by pharmacotherapy might be a promising way to treat preeclampsia. Interestingly, many of the drugs adopted for the prevention and treatment of preeclampsia have been found to regulate NFĸB activity. Despite this, further innovation is urgently needed to ensure treatment safety and efficacy. The present article summarizes the current state of knowledge about the drugs recommended by cardiology, obstetrics, and gynaecology societies for the prevention and treatment of preeclampsia with regard to their impact on the cellular regulation of NFĸB pathways. |
| first_indexed | 2024-03-09T20:36:20Z |
| format | Article |
| id | doaj.art-d08441be16a64a76a0c4ef2c215bb6c8 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T20:36:20Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-d08441be16a64a76a0c4ef2c215bb6c82023-11-23T23:11:11ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-03-01235288110.3390/ijms23052881The Targeting of Nuclear Factor Kappa B by Drugs Adopted for the Prevention and Treatment of PreeclampsiaAgata Sakowicz0Department of Medical Biotechnology, Medical University of Lodz, 90-752 Lodz, PolandPreeclampsia (PE) is characterised by high levels and activity of the transcription factor Nuclear Factor kappa B (NFĸB) in the maternal blood and placental cells. This factor is responsible for the regulation of over 400 genes known to influence processes related to inflammation, apoptosis and angiogenesis, and cellular responses to oxidative stress and hypoxia. Although high NFĸB activity induces hypoxia and inflammation, which are beneficial for the process of implantation, NFĸB level should be reduced in the later stages of physiological pregnancy to favour maternal immunosuppression and maintain gestation. It is believed that the downregulation of NFĸB activity by pharmacotherapy might be a promising way to treat preeclampsia. Interestingly, many of the drugs adopted for the prevention and treatment of preeclampsia have been found to regulate NFĸB activity. Despite this, further innovation is urgently needed to ensure treatment safety and efficacy. The present article summarizes the current state of knowledge about the drugs recommended by cardiology, obstetrics, and gynaecology societies for the prevention and treatment of preeclampsia with regard to their impact on the cellular regulation of NFĸB pathways.https://www.mdpi.com/1422-0067/23/5/2881Nuclear Factor kappa Bpreeclampsiaprevention of preeclampsiatreatment |
| spellingShingle | Agata Sakowicz The Targeting of Nuclear Factor Kappa B by Drugs Adopted for the Prevention and Treatment of Preeclampsia International Journal of Molecular Sciences Nuclear Factor kappa B preeclampsia prevention of preeclampsia treatment |
| title | The Targeting of Nuclear Factor Kappa B by Drugs Adopted for the Prevention and Treatment of Preeclampsia |
| title_full | The Targeting of Nuclear Factor Kappa B by Drugs Adopted for the Prevention and Treatment of Preeclampsia |
| title_fullStr | The Targeting of Nuclear Factor Kappa B by Drugs Adopted for the Prevention and Treatment of Preeclampsia |
| title_full_unstemmed | The Targeting of Nuclear Factor Kappa B by Drugs Adopted for the Prevention and Treatment of Preeclampsia |
| title_short | The Targeting of Nuclear Factor Kappa B by Drugs Adopted for the Prevention and Treatment of Preeclampsia |
| title_sort | targeting of nuclear factor kappa b by drugs adopted for the prevention and treatment of preeclampsia |
| topic | Nuclear Factor kappa B preeclampsia prevention of preeclampsia treatment |
| url | https://www.mdpi.com/1422-0067/23/5/2881 |
| work_keys_str_mv | AT agatasakowicz thetargetingofnuclearfactorkappabbydrugsadoptedforthepreventionandtreatmentofpreeclampsia AT agatasakowicz targetingofnuclearfactorkappabbydrugsadoptedforthepreventionandtreatmentofpreeclampsia |